132 related articles for article (PubMed ID: 15467439)
21. Rosetting of human T lymphocytes with sheep and human erythrocytes. Comparison of human and sheep ligand binding using purified E receptor.
Selvaraj P; Dustin ML; Mitnacht R; Hünig T; Springer TA; Plunkett ML
J Immunol; 1987 Oct; 139(8):2690-5. PubMed ID: 3309056
[TBL] [Abstract][Full Text] [Related]
22. The "erythrocyte receptor" of T-lymphocytes and T11 target structure (T11TS): complementary cell interaction molecules involved in T-cell activation.
Hünig T; Tiefenthaler G; Mitnacht R; Köhler C; Lottspeich F; Meuer S
Behring Inst Mitt; 1987 Jun; (81):31-40. PubMed ID: 2888455
[TBL] [Abstract][Full Text] [Related]
23. A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals.
Demetriou P; Abu-Shah E; Valvo S; McCuaig S; Mayya V; Kvalvaag A; Starkey T; Korobchevskaya K; Lee LYW; Friedrich M; Mann E; Kutuzov MA; Morotti M; Wietek N; Rada H; Yusuf S; Afrose J; Siokis A; ; Meyer-Hermann M; Ahmed AA; Depoil D; Dustin ML
Nat Immunol; 2020 Oct; 21(10):1232-1243. PubMed ID: 32929275
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic intervention of glioma with the novel antineoplastic agent T11TS: the story so far.
Chaudhuri S; Acharya S; Chaudhuri S
Immunotherapy; 2022 Oct; 14(15):1263-1277. PubMed ID: 36004447
[TBL] [Abstract][Full Text] [Related]
25. T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.
Bhattacharya D; Chaudhuri S; Singh MK; Chaudhuri S
Exp Mol Pathol; 2015 Jun; 98(3):455-66. PubMed ID: 25797371
[TBL] [Abstract][Full Text] [Related]
26. T11TS, the cell surface molecule binding to the "erythrocyte receptor" of T lymphocytes: cellular distribution, purification to homogeneity and biochemical properties.
Hünig T; Mitnacht R; Tiefenthaler G; Köhler C; Miyasaka M
Eur J Immunol; 1986 Dec; 16(12):1615-21. PubMed ID: 2880724
[TBL] [Abstract][Full Text] [Related]
27. The CD2-CD58 axis: A novel marker predicting poor prognosis in patients with low-grade gliomas and potential therapeutic approaches.
Wu M; Chen Y; Hua G; Chunhui L
Immun Inflamm Dis; 2023 Oct; 11(10):e1022. PubMed ID: 37904707
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Changes in Immunoreactivity and Cellular Architecture during the Progressive Development of Intracranial Neoplasms and an Immunotherapeutic Schedule with a Novel Biological Response Modifier, the T11TS / S-LFA3.
Mukherjee J; Dutta S; Sarkar S; Begum Z; Ghosh A; Chaudhuri S; Chaudhuri S
Asian Pac J Cancer Prev; 2002; 3(4):325-337. PubMed ID: 12716291
[TBL] [Abstract][Full Text] [Related]
29. Comparative evaluation of T11 target structure and its deglycosylated derivative nullifies the importance of glycan moieties in immunotherapeutic efficacy.
Chatterjee S; Acharya S; Kumar P; Chatterjee A; Chaudhuri S; Ghosh A; Chaudhuri S
Acta Biochim Biophys Sin (Shanghai); 2012 Mar; 44(3):259-68. PubMed ID: 22257732
[TBL] [Abstract][Full Text] [Related]
30. Induction of G1 arrest in glioma cells by T11TS is associated with upregulation of Cip1/Kip1 and concurrent downregulation of cyclin D (1 and 3).
Acharya S; Chatterjee S; Kumar P; Bhattacharjee M; Chaudhuri S; Chaudhuri S
Anticancer Drugs; 2010 Jan; 21(1):53-64. PubMed ID: 19829098
[TBL] [Abstract][Full Text] [Related]
31. The role of CD2/LFA-3 interaction in antigen- and mitogen-induced activation of human T cells.
Tiefenthaler G; Hünig T
Int Immunol; 1989; 1(2):169-75. PubMed ID: 2484882
[TBL] [Abstract][Full Text] [Related]
32. Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.
Veldman J; Visser L; Huberts-Kregel M; Muller N; Hepkema B; van den Berg A; Diepstra A
Blood; 2020 Nov; 136(21):2437-2441. PubMed ID: 32589698
[TBL] [Abstract][Full Text] [Related]
33. Activation of human T lymphocytes through CD3 and CD2 (T11) with anti-CD3-coupled sheep erythrocytes.
Ocklind G
Scand J Immunol; 1988 May; 27(5):609-13. PubMed ID: 2897712
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of anti-tumor property of specific and non-specific BRMs in experimental gioma by assessing the microglial cell functional and phenotypic modulations.
Begum Z; Sarkar S; Mukherjee J; Ghosh A; Chaudhuri S; Chaudhuri S
Cancer Biol Ther; 2003; 2(4):356-63. PubMed ID: 14508105
[TBL] [Abstract][Full Text] [Related]
35. Costimulatory Function of Cd58/Cd2 Interaction in Adaptive Humoral Immunity in a Zebrafish Model.
Shao T; Shi W; Zheng JY; Xu XX; Lin AF; Xiang LX; Shao JZ
Front Immunol; 2018; 9():1204. PubMed ID: 29904386
[TBL] [Abstract][Full Text] [Related]
36. Regulation of key molecules of immunological synapse by T11TS immunotherapy abrogates Cryptococcus neoformans infection in rats.
Sk Md OF; Hazra I; Datta A; Mondal S; Moitra S; Chaudhuri S; Das PK; Basu AK; Mishra R; Chaudhuri S
Mol Immunol; 2020 May; 122():207-221. PubMed ID: 32388483
[TBL] [Abstract][Full Text] [Related]
37. Purified lymphocyte function-associated antigen-3 and T11 target structure are active in CD2-mediated T cell stimulation.
Tiefenthaler G; Hünig T; Dustin ML; Springer TA; Meuer SC
Eur J Immunol; 1987 Dec; 17(12):1847-50. PubMed ID: 2891540
[TBL] [Abstract][Full Text] [Related]
38. All CD2-positive human lymphocytes rosette with sheep erythrocytes in the presence of polyethylene glycol.
Ocklind G
J Immunol Methods; 1988 Sep; 112(2):169-72. PubMed ID: 2901445
[TBL] [Abstract][Full Text] [Related]
39. Influence of multiple delays in brain tumor and immune system interaction with T11 target structure as a potent stimulator.
Khajanchi S; Banerjee S
Math Biosci; 2018 Aug; 302():116-130. PubMed ID: 29908145
[TBL] [Abstract][Full Text] [Related]
40. The other side of the coin: beneficiary effect of 'oxidative burst' upsurge with T11TS facilitates the elimination of glioma cells.
Ghosh A; Mukherjee J; Bhattacharjee M; Sarkar P; Acharya S; Chaudhuri S; Chaudhuri S
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(5):53-62. PubMed ID: 17543233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
